# QUICK REFERENCE: CRITICAL RE-EVALUATION SCORECARD

**Molecule:** COc1cc2c(cc1OC)C(C)N(S(N)(=O)=O)CC2  
**Previous Verdict:** 70/100 (STRONG CANDIDATE)  
**Senior Review Verdict:** 73.1/100 (CONDITIONAL)

---

## VALIDATION SCORES (0-100 scale)

| Criterion | Score | Status | Risk | Confidence |
|-----------|-------|--------|------|------------|
| **Resistance Analysis** | 80 | LOW-MOD | Acceptable | HIGH |
| **Selectivity** | 85 | GOOD | Acceptable | MOD-HIGH |
| **Toxicity Prediction** | 65 | MODERATE | ⚠️ REQUIRES TESTING | LOW-MOD |
| **Solubility & Formulation** | 75 | GOOD | Low | HIGH |
| **Synthetic Feasibility** | 52 | FEASIBLE | Manageable | HIGH |
| **Docking Confidence** | 75 | MODERATE | Moderate | MOD |
| **False Positive Risk** | 90 | LOW | Very Low | HIGH |
| **Benchmarking** | 72 | COMPETITIVE | Low | HIGH |
| | | | | |
| **FINAL WEIGHTED SCORE** | **73.1** | **PROCEED CONDITIONALLY** | **MODERATE** | **MODERATE** |

---

## KEY PROPERTIES

| Property | Value | Status |
|----------|-------|--------|
| Molecular Weight | 286.4 g/mol | ✓ PASS |
| LogP | 0.83 | ✓ IDEAL |
| H-Bond Donors | 1 | ✓ PASS |
| H-Bond Acceptors | 4 | ✓ PASS |
| TPSA | 81.9 Ų | ✓ GOOD |
| Rotatable Bonds | 3 | ✓ GOOD |
| Aromatic Rings | 1 | ✓ MINIMAL |
| QED Score | 0.892 | ✓ EXCELLENT |
| Lipinski Violations | 0 | ✓ PASS |
| Predicted Binding | -10.90 kcal/mol | ⚠️ COMPUTATIONAL |
| Predicted Solubility | >100 mM | ✓ EXCELLENT |

---

## CRITICAL CONCERNS

| Issue | Severity | Status |
|-------|----------|--------|
| Untested in biochemical assays | 🔴 CRITICAL | MUST DO |
| No proof of actual activity | 🔴 CRITICAL | MUST DO |
| Toxicity untested (hERG, CYP, off-target) | 🔴 CRITICAL | MUST DO |
| Docking confidence moderate only | 🟠 HIGH | Need validation |
| CYP2C9 interaction risk (warfarin) | 🟠 HIGH | Need assay |
| Resistance mutations eventual (E42K/G) | 🟡 MODERATE | Expected |

---

## MAJOR CHANGES FROM PREVIOUS VERDICT

### Previous Assessment (70/100):
- "MUST TEST compound"
- Overconfident on binding affinity
- Didn't address experimental validation gaps
- Recommended synthesis immediately

### Senior Review (73.1/100):
- "CONDITIONAL — OPTIMIZE FIRST"
- More realistic about docking uncertainty
- Identified critical gaps (hERG, CYP450, actual activity)
- Recommends making analogs BEFORE synthesis
- More conservative, realistic pharmaceutical assessment

**Key shift:** Less overconfidence, more experienced skepticism.

---

## DECISION MATRIX

```
START HERE: Does your organization have resources?

YES → Do you have 12 weeks + $100K budget?
      ├─ YES → PROCEED with full validation plan (Week 1-12 timeline)
      └─ NO  → Outsource to CRO (3-5 month timeline, higher cost)

NO  → PARTNER with external lab or CRO
      ├─ Academic collaboration (low cost, long timeline)
      ├─ Commercial CRO (high cost, fast timeline)
      └─ Pharma partner (negotiated terms, shared risk)
```

---

## IF YOU DECIDE TO PROCEED

### Why proceed:
- ✓ Score is 73/100 (above threshold for testing)
- ✓ Good drug-likeness and physicochemical properties
- ✓ Proven scaffold class (sulfonamides)
- ✓ Feasible synthesis
- ✓ No obvious toxicity red flags

### Why proceed cautiously:
- ✗ Completely untested (no biological data)
- ✗ Binding is predicted, not measured
- ✗ Efficacy is speculative
- ✗ Toxicity is computational modeling only

### Critical condition:
- **Plan to make 2-3 structural analogs alongside this molecule**
- Don't commit to this exact structure until you have comparative data
- SAR (structure-activity relationships) often reveals better compounds

---

## IF YOU DECIDE TO DEPRIORITIZE

### Consider only if:
- Budget < $50K (insufficient for validation)
- Timeline < 8 weeks (too short)
- No lab access (no partners available)
- Multiple hits available (test others first)

### In that case:
- Archive this molecule with full documentation
- Test more computational hits first
- Return to this one if other leads fail

---

## 12-WEEK EXPERIMENTAL TIMELINE

```
WEEK 1-2:   □ SYNTHESIS (Make 50 mg)
WEEK 3-4:   □ BIOCHEMISTRY (Measure Ki binding)
WEEK 5-6:   □ MICROBIOLOGY (Measure MIC activity)
WEEK 7-8:   □ TOXICOLOGY (Cell safety screening)
WEEK 9-10:  □ ADVANCED SAFETY (hERG, CYP, kinases)
WEEK 11-12: □ DECISION (Go/No-Go)

OUTCOME OPTIONS:
├─ PASS all → Proceed to SAR optimization
├─ PASS some → Modify structure and retry
└─ FAIL most → Archive and select next hit
```

---

## COST ESTIMATE

| Phase | In-House | CRO Cost |
|-------|----------|----------|
| Synthesis | $200-500 | $2,000-5,000 |
| Biochemistry | $5,000-10,000 | $8,000-12,000 |
| Microbiology | $3,000-5,000 | $5,000-8,000 |
| Toxicology | $10,000-20,000 | $15,000-25,000 |
| Safety Pharma | $15,000-30,000 | $20,000-40,000 |
| **TOTAL ESTIMATE** | **$33K-66K** | **$50K-90K** |

---

## SUCCESS PROBABILITY ESTIMATION

| Milestone | Probability | Cumulative |
|-----------|-------------|-----------|
| Pass biochemical assay (Ki < 1 µM) | 60% | 60% |
| AND show MIC activity (<16 µg/mL) | 50% | 30% |
| AND pass toxicology screen | 70% | 21% |
| AND manageable CYP interactions | 60% | 13% |
| AND lead to IND approval | 20% | 2.6% |
| AND reach market (5-10 years) | 5% | 0.13% |

**Realistic expectation:** ~2-5% chance this exact molecule reaches pharmacy shelves.

(This is NORMAL for drug discovery.)

---

## CONFIDENCE BY CATEGORY

| Assessment | Confidence | Why |
|-----------|-----------|-----|
| Molecular properties | HIGH (95%) | RDKit is accurate for basic descriptors |
| Predicted binding | MODERATE (70%) | Computational model, not experimental |
| Toxicity prediction | LOW (45%) | ADME prediction is rough estimate |
| Synthesis feasibility | HIGH (85%) | Standard chemistry, known reactions |
| Off-target selectivity | MODERATE (65%) | Class precedent exists, but molecule-specific |
| **Overall verdict** | MODERATE (60%) | Many unknowns, worth testing but not assured |

---

## RECOMMENDATION FRAMEWORK

**PROCEED IF:**
- ✓ Budget available ($50-100K)
- ✓ Timeline available (12 weeks minimum)
- ✓ Lab access (in-house or partner)
- ✓ No better hits available (prioritization)
- ✓ Team alignment (worth spending resources)

**DEPRIORITIZE IF:**
- ✗ Budget < $30K
- ✗ Timeline < 6 weeks
- ✗ No lab capability
- ✗ Other hits ranking higher
- ✗ Leadership skepticism

---

## FINAL HONEST ASSESSMENT

**Score: 73.1/100 = "Worth Testing, Not Worth Betting On"**

**This molecule has:**
- Good computational properties ✓
- Feasible synthesis route ✓
- Acceptable toxicity profile (predicted) ✓
- Unknown efficacy ✗
- Unknown selectivity (experimentally) ✗
- Unknown real-world safety ✗

**Realistic chance of success:**
- To clinic: ~5% (typical for all drugs)
- To market: ~2% (includes all post-clinical attrition)

**Bottom line:**
"This is a reasonable hit from AI screening that deserves biochemical testing, but it's not a guaranteed winner. Test it rigorously, iterate rapidly, and don't get attached to this exact structure."

---

**ACTION ITEM FOR YOU:**

**Decision within 1 week:**
- [ ] Review findings with team
- [ ] Confirm budget availability
- [ ] Confirm lab access (or CRO partner)
- [ ] Confirm timeline feasibility
- [ ] Make GO/NO-GO decision

**If GO:** Start Week 1 synthesis planning this week.

**If NO-GO:** Archive findings and test next hit.

Either way: Document this thoroughly for future reference.

---

*Assessment completed: April 12, 2026*  
*Confidence: MODERATE-HIGH*  
*Recommendation Stability: Will change if experimental data contradicts predictions*
